3-(2-methyl-propenyl)-pyridine | 2682-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2-methyl-propenyl)-pyridine
• 英文别名: 3-(2-Methylprop-1-en-1-yl)pyridine；3-(2-methylprop-1-enyl)pyridine
• CAS: 2682-90-8
• 化学式: C₉H₁₁N
• 分子量: 133.193
• InChiKey: IGJUDJGFQPGZAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-吡啶甲醛 、 alkaline earth salt of/the/ methylsulfuric acid 在 hexamethyldisilazide 作用下， 生成 3-(2-methyl-propenyl)-pyridine
  参考文献：
  名称：

  Development of a polymer bound Wittig reaction and use in multi-step organic synthesis for the overall conversion of alcohols to β-hydroxyamines

  摘要：

  通过聚合物负载高铼酸盐（PSP）将醇温和氧化为醛，随后使用聚合物负载的Wittig试剂对所得醛进行清洁的烯化反应，接着用二甲基二氧杂环丙烷（DMDO）对烯烃进行环氧化，最后用各种胺对环氧化物进行胺解反应，实现了一种适用于自动化的β-羟基胺的高效组合合成方法。

  DOI：

  10.1039/a803612h

文献信息

• Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]
  申请人：Phenex Pharmaceuticals AG

  公开号：US10301272B2

  公开（公告）日：2019-05-28

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了孤儿核受体RORy的调节剂，以及通过向人类或有需要的哺乳动物施用这些新型RORy调节剂来治疗RORy介导的疾病的方法。具体地说，本发明提供了式(1)、(1′)、(100)、(100′)、(200)和(200′)的含羧酰胺或磺酰胺的环状化合物及其对映体、非对映体、同系物、/V-氧化物、溶剂和药学上可接受的盐。
• Aryl cyclopropyl-amino-isoquinolinyl amide compounds
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US11312700B2

  公开（公告）日：2022-04-26

  Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.

  本文提供的是芳基环丙基氨基异喹啉酰胺化合物。特别是，本公开提供的化合物可影响细胞中激酶的功能，并可作为治疗剂或与治疗剂一起使用。本公开的化合物可用于治疗多种疾病和病症，包括眼部疾病（如青光眼）、心血管疾病、以异常生长为特征的疾病（如癌症）以及炎症性疾病。本公开进一步提供了含有异喹啉酰胺化合物的组合物。
• Anti-Bacterial Compounds
  申请人：Parker Jane Katy

  公开号：US20080096894A1

  公开（公告）日：2008-04-24

  Compounds of formula (I), or salts or solvates thereof, in vitro as inhibitors of growth of Gram-positive bacteria, where A is selected from formula (a).
• ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20210002253A1

  公开（公告）日：2021-01-07

  Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.
• MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20210002254A1

  公开（公告）日：2021-01-07

  Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.